MARKET

EPIX

EPIX

ESSA Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.860
-0.190
-6.23%
After Hours: 2.860 0 0.00% 16:05 09/20 EDT
OPEN
2.900
PREV CLOSE
3.050
HIGH
3.003
LOW
2.820
VOLUME
94.39K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.410
MARKET CAP
59.38M
P/E (TTM)
-1.6057
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EPIX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EPIX News

  • ESSA to Present at Ladenburg Thalmann Healthcare Conference
  • PR Newswire.3d ago
  • 58 Biggest Movers From Yesterday
  • Benzinga.09/13 11:04
  • ESSA Pharma closes $36M capital raise
  • seekingalpha.08/27 20:23
  • ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
  • CNW Group.08/27 14:21

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About EPIX

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. Its pipeline also includes antinen for triple negative androgen receptor (AR+) breast cancer. Its proprietary aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting ARdriven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.
More

Webull offers ESSA Pharma Inc (EPIX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.